Combination of the PARP1-selective Inhibitor AZD5305 with the ATR Inhibitor Ceralasertib for the Treatment of PARPi-resistant Cancer
MOLECULAR CANCER THERAPEUTICS（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined